Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

New AI hub in London brings together engineers, AI specialists and scientists to reduce the time to market for future medicines

12-Aug-2026
AI-generated image

Symbolic image

Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernise Novo Nordisk’s operations through agentic AI and cloud technologies. As part of the partnership, Novo Nordisk and AWS have created a co-innovation hub in London where engineers and scientists from both companies are using AWS AI technologies alongside Novo Nordisk data and insights to compress the path from drug target to first human dose.

“Partnering with AWS is about making AI a driver of innovation across Novo Nordisk,” said Mike Doustdar, president and CEO of Novo Nordisk. “By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases.”

Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner, bringing together Novo Nordisk's deep therapeutic knowledge across chronic diseases and AWS's world-leading cloud and AI services, secure and scalable infrastructure, and life sciences technologies. Novo Nordisk has already seen measurable results from this collaboration, including reducing clinical documentation time and empowering more than 25,000 employees to boost productivity. This new agreement builds on a longstanding relationship and will create the secure foundations needed to turn ideas into new therapies for patients around the world. This includes using services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging and clinical data so that breakthroughs in early research can shape clinical trial design. Novo Nordisk will also leverage Amazon Bedrock AgentCore to drive efficiencies across its operations through AI agents.

"Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster," said Matt Garman, CEO, AWS. "Novo Nordisk has chosen AWS as their strategic AI partner to fundamentally change how medicines are discovered and developed using services such as Amazon Bio Discovery and Amazon Bedrock. We’re excited to partner with Novo Nordisk so that these technologies, AWS Forward Deployed Engineers, and Novo Nordisk’s industry-leading science teams can help compress drug discovery timelines, securely process complex datasets, and scale findings across therapeutic areas.”

Novo Nordisk collaborates with multiple Amazon businesses that support the healthcare industry, including Amazon Pharmacy, Amazon Ads, and Amazon One Medical, to transform how new therapies are marketed and delivered to patients.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Dharmacon's completion of first human genome-wide siRNA library signals new era in life-science research

Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Stora Enso and Gasum to make renewable energy from wastewater in Sweden

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Antibiotic-Resistant Bacteria Have Evolved a Unique Chemical Mechanism, New Discovery Reveals